The<unk>  is a complicated issue with an extremely wide range of<unk> s due to varying factors such as the type of antiretroviral therapy and the country in which the<unk>  is administered. The first line therapy of<unk> , or the initial antiretroviral drug regimen for an<unk> -infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest<unk>  of antiretroviral therapy, while middle- and high-income tend to have considerably higher<unk> s. Certain prices of<unk>  drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater<unk>  drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of<unk>  drugs. In 2019 the government of India reported that it was supplying 2/3 of drugs for<unk><unk> .
Cost of HIV treatment
Personal medicine
Cancer insurance
Social insurance
Access to medicines
Cost of drug development
Personal health application
Drug policy